Skip to content
-
NASP’s comments to FTC’s Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics Workshop
Dec 12, 2017
NASP represents an industry that focuses on providing high quality patient care first with an added... read more
-
Looking for Leadership from HHS Secretary Nominee Alex Azar on Requiring Transparency from Big PBMs and Reducing Specialty Medication Costs for Sick Seniors
Nov 17, 2017
FOR IMMEDIATE RELEASE WASHINGTON, D.C. (November 16, 2017) – President Trump’s new nominee for Health and... read more
-
Diverse Health Care Providers & Stakeholders Urge President Trump to Appoint Rep. Earl “Buddy” Carter to Commission on Containing Costs of Lifesaving Prescription Drugs
Oct 26, 2017
FOR IMMEDIATE RELEASE View Press Release Coalition Commends Rep. Carter’s Record of Working to Enhance Clinical... read more
-
Rep. Tom Suozzi (NY3) Visits Great Neck Oncology Pharmacy to Tour, Discuss, & Learn the Importance of Specialty Pharmacy for Cancer Patients & Caregivers
Oct 24, 2017
FOR IMMEDIATE RELEASE New York (Oct. 19) – Today, Rep. Tom Suozzi (D – Long Island, Queens) met with... read more
-
Ensuring Rebates and Discounts in Medicare Part D Help Reduce Patient OOP Costs
Oct 05, 2017
Please click here for the final signed copy of the letter Rep. Buddy Carter championed and... read more
-
National Association of Specialty Pharmacy Dismisses PBM-Funded Report Claiming Drug Cost Savings from Direct & Indirect Remuneration (DIR) Fees
Aug 04, 2017
View Press Release DIR fees continue to inflate prescription drug costs for the sickest, most vulnerable... read more
-
NASP Applauds CMS for Enhancing Oversight & Holding Large Pharmacy Benefit Managers Accountable for Rising Drug Costs
Jun 20, 2017
FOR IMMEDIATE RELEASE View Press Release National Association of Specialty Pharmacy Applauds CMS for Enhancing Oversight... read more
-
NASP’s comments to CMS’ Proposed Medicare Part D DIR Reporting Requirements for 2016
Jun 02, 2017
NASP represents an industry that focuses on providing quality patient care first with an added emphasis... read more
-
NASP White Paper: “Performance” Based DIR Fees: A Rigged System with Disparate Effect on Specialty Pharmacies, Medicare Part D Beneficiaries and the U.S. Healthcare System
Mar 20, 2017
On behalf of National Association of Specialty Pharmacy, the Executive Board commissioned a white paper (Performance”... read more
-
NASP Response to Centers for Medicare & Medicaid Services (CMS) Comments Regarding Draft 2018 Call Letter
Mar 10, 2017
NASP represents an industry that focuses on providing quality patient care first with an added emphasis... read more